Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 12 of 12 publications.
Skip to main content
Mayer SE, Kawai A, Fuller CC, Agan AA, Rao S, Koram N, Calingaert B, Marshall J, Connolly JG, Moyneur E, Jamal-allial A, Brown J, Burk J, Chomistek A, Daniels K, Dea K, DeFor TA, Diessner B, Djibo DA, Ezzy S, Hawrusik R, Johannes CB, Kendrick K, Layton JB, Ma Q, Mai X, Mack M, Pawloski PA, Reynolds JS, Selvan M, Sharma V, Vetter J, McMahill-Walraven CN, Platt R, Gilsenan A. Interim utilization results from a post-approval safety study of Pfizer-BioNTech monovalent COVID-19 vaccine in the United States. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Danysh HE, Gilsenan A, Kaye JA, Garcia de Albeniz Martinez X, Schmid R, Bartsch J, Calingaert B, Rahman S, Layton JB, Gutierrez L. Validation of algorithms to identify breast cancer and bladder cancer among patients with type 2 diabetes mellitus in United States medicare administrative claims. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.
Gilsenan AW. Depression and pain in the primary care setting. Presented at the Correlation Between Depression and Pain: Creating a New Treatment Paradigm to Evaluate Cost and Caliber of Care. Symposia at the Academy of Managed Care Pharmacy 2002 Educational Conference; October 2002. Washington, DC.
Andrews EB, Mitchell AA, Seligman P, Cook SF, Gilsenan AW. Risk management: what are we driving, where are we going, and how will we know when we get there? Presented at the 18th International Conference on Pharmacoepidemiology; August 2002.
Longo C, Raskin J, Gilsenan AW, Corey-Lisle P, Hopkins JS, Sherrill BH. Prevalence of treatment-resistant depression in Saskatchewan - limitations of a claims-based analysis. Int J Neuropsychopharmacol. 2002 Jun 1;5(Suppl 1):S141. doi: 10.1017/S1461145702003176
Longo CJ, Raskin J, Gilsenan AW, Corey-Lisle P, Sherrill EH, Hopkins JS. Prevalence of treatment-resistant depression in Saskatchewan—limitations of a claims based analysis. Poster presented at the XXIII CINP Congress; 2002.
West SL, Dever JA, Troutman KS, Gilsenan AW, Glasser D. Methodology for conducting a national population-based prevalence study of erectile dysfunction. Poster presented at the 18th International Conference on Pharmacoepidemiology; 2002.
Gilsenan AW, Hopkins JS, Sherrill EH, Corey-Lisle PK, Longo CJ, Raskin J. Prevalence and costs of treatment-resistant depression in a Canadian claims database. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.
Pendergast KB, Gilsenan AW, West SL, Swindle RW, Kroenke K. Differences in psychological and other quality of life dimensions in depressed patients identified as low-risk or high-risk for suicide. Poster presented at the 18th International Conference on Pharmacoepidemiology; 2002.
Von Scheele BG, Sherrill EH, Gilsenan AW, Devlin P. Therapeutic interchangeability of levothyroxine. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.
Hopkins JS, Gilsenan AW, Sherrill EH, Cory-Lisle PK, Longo CJ, Raskin J. Methods to identify treatment-resistant depression in a Canadian claims database. Poster presented at the International Society for Pharmacoepidemiology Conference; 2002.